Table 1. Impact of B cells on tumor growth in murine cancer models.
| Year | Mouse model | Cell line or carcinogen | Tumor type | Tumor growth on B-cell deficiency | Phenotypic markers | Ref. |
|---|---|---|---|---|---|---|
|
2005 |
Rag1−/− Cd4−/− Cd8−/− |
HPV16 (transgenic) |
Skin cancer |
Reduced |
- |
27
|
|
2005 |
C57BL/6 |
EL4 cells MC38 cells B16/F10 cells |
Lymphoma Colon cancer Melanoma |
Reduced Reduced Enhanced |
- |
28
|
|
2006 |
C57BL/6 |
EL-4 cells D5 cells MCA304 cells |
Lymphoma Melanoma Sarcoma |
Reduced Reduced No change |
- |
24
|
|
2010 |
C57BL/6 |
TRAMP (transgenic) |
Prostate cancer |
Reduced |
- |
29
|
|
2010 |
C57BL/6 |
B16/F10 cells |
Melanoma |
Enhanced |
- |
30
|
|
2011 |
C57BL/6 |
DMBA/TPA |
Skin cancer |
Reduced |
CD19+CD21+IL10+ |
26
|
| 2012 | BALB/c C57BL/6 NOD/SCID |
4T1 cells | Breast cancer | Reduced | CD19+ CD25high B7-H1high CD81high CD86highCCR6high CD62LlowIgMint/low |
42 |
DMBA, 7,12-dimethylbenz[α]anthracen; HPV16, human papillomavirus type 16; TPA, 12-O-tetradecanoylphorbol-13-acetate; TRAMP, transgenic adenocarcinoma of mouse prostate.